Differences in medication adherence and healthcare resource utilization patterns: Older versus newer antidepressant agents in patients with depression and/or anxiety disorders

CNS Drugs

Volumn 22, Issue 11, 2008, Pages 963-973

  Sheehan, David V ^a   Keene, Matthew S ^b   Eaddy, Michael ^c   Krulewicz, Stan ^d   Kraus, John E ^d   Carpenter, David J ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Medco Health Solutions   (United States)

^c XCENDA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Antidepressants, therapeutic use; Anxiety, treatment; Bupropion, therapeutic use; Cost analysis; Depression, treatment; Dopamine uptake inhibitors, therapeutic use; Duloxetine, therapeutic use; Escitalopram, therapeutic use; Hospitalisation; Managed care

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; COMORBIDITY; DATA ANALYSIS; DATA BASE; DEPRESSION; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DEPRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; UNITED STATES;

EID: 53549130993     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822110-00005     Document Type: Article

References (29)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
3. Murray CJ, Jopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349 (9064): 1498-504
4. Arikian SR, Gorman JM. A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders. Prim Care Companion J Clin Psychiatry 2001; 3 (3): 110-7
5. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64: 1465-75
6. National Institute of Mental Health. Anxiety disorders [online]. Available from URL: http://www.nimh.nih.gov/publicat/anxiety.cfm#14 [Accessed 2007 Jun 25]
7. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
8. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171-99
9. Sramek JJ, Zarotsky V, Cutler NR. Generalized anxiety disorder. Drugs 2002; 11: 1635-48
10. Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003; 6 (4): 427-42
11. Zohar J, Keeqstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multi-center double blind study. Hum Psychopharmacol 2003; 18 (2): 113-9
12. IMS Health. 2004 year-end U.S. prescription and sales information and commentary [online]. Available from URL: http://www.imshealth.com/ims/portal/ front/articleC/0,2777,6599_3-665_69890098,00.html [Accessed 2006 Dec 5]
13. Keene MS, Eaddy MT, Mauch RP, et al. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). Curr Med Res Opin 2005; 21 (10): 1651-8
14. Keene MS, Eaddy MT, Nelson WW, et al. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care 2005; 11 Suppl. 12: S362-9
15. Sheehan DV, Eaddy MT, Shah MB, et al. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care 2005; 11 Suppl. 12: S354-61
16. Eaddy MT, Bramley T, Regan TS. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin reuptake inhibitors. Manag Care Interface 2003; 16: 22-7
17. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31 (2): 122-31
18. Rush AJ, Trivedi MH, Wisniewski SR. Bupropion SR, sertraline, venlafaxine XR after failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1231-42
19. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended-release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005; 22 (2): 68-76
20. Silverstone PH, Ravindran A. Once-daily venlafaxine extended-release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine 360 Study Group. J Clin Psychiatry 1999; 60 (1): 22-8
21. Boulenger JP, Huusom AKT, Florea I, et al. A comparative study of the efficacy and tolerability of long-term treatment with escitalopram and paroxetine in severe major depression [poster]. International Conference on Anxiety Disorders; 2006 Feb 24-26; Stellenbosch
22. International classification of diseases, 9th revision, clinical modification (ICD-9-CM). Geneva: World Health Organization, 2007
23. Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-16
24. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006; 44 (4): 300-3
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83
26. Deyo R, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9
27. Eaddy M, Sarnes M, Regan T, et al. Examining the relationship between length of selective serotonin reuptake inhibitor treatment and the risk of hospitalization in a naturalistic managed care setting [poster]. Academy of Managed Care Pharmacy 2004 Educational Conference; 2004 Oct 13-16; Baltimore (MD)
28. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 2000; 177: 163-8
29. Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007 Feb; 10 (1): 51-61.